Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

NCT03430466 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Recruiting was not possible

Conditions

Breast Cancer

Interventions

DRUG: Durvalmab&Tremelimumab&Fulvestrant

Sponsor

Kyoto Breast Cancer Research Network